{"id":"W4382752021","doi":"10.1182/blood.2022018818","title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; BeiGene; AstraZeneca","keywords":"Ibrutinib; Medicine; Internal medicine; Hazard ratio; Adverse effect; Discontinuation; Chronic lymphocytic leukemia; Incidence (geometry); Confidence interval; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003165975,0.0004090444,0.001265607,0.0002621266,0.0002171192,0.000829249,0.0002597128,0.0003909022,0.002483116],"category_scores_gemma":[0.001768528,0.0001468314,0.001928181,0.0003895428,0.0002582973,0.0004653321,0.0002609815,0.001311802,0.0003593502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003734335,"about_ca_system_score_gemma":0.0004415906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002847044,"about_ca_topic_score_gemma":0.001159904,"domain_scores_codex":[0.998867,0.0006210889,0.0001151262,0.0001196726,0.0001676587,0.0001093927],"domain_scores_gemma":[0.9992024,0.0002953564,0.0002388899,0.00007984361,0.00007027088,0.0001132231],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7042834,0.005782397,0.02914597,0.00347326,0.01461422,0.0002706162,0.0002819554,0.005733903,0.0388341,0.0008443733,0.009077904,0.1876579],"study_design_scores_gemma":[0.3975707,0.3478077,0.1845206,0.0004687211,0.0137647,0.001103029,0.0001858425,0.005381242,0.01216575,0.001768505,0.03512017,0.0001430966],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781424,0.01264294,0.0007506836,0.0004002044,0.0001012941,0.000623656,0.002496507,0.0001027892,0.004739435],"genre_scores_gemma":[0.9926922,0.002378551,0.0003516765,0.0004668412,0.0001422465,0.0005443582,0.002355505,0.00002094393,0.001047641],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003165975,"threshold_uncertainty_score":0.01674348,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02521432312752855,"score_gpt":0.303973250273012,"score_spread":0.2787589271454835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}